Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2020 / Cilt: 28 - Sayı: 1

Evaluation of epidermal growth factor receptor mutations and thyroid transcription factor-1 status in Turkish non-small cell lung carcinoma patients: A study of 600 cases from a single center

Küçük hücreli dışı akciğer karsinomlu Türk hastalarda epidermal büyüme faktör reseptör mutasyonları ve tiroid transkripsiyon faktör-1 durumunun değerlendirilmesi: Tek merkezli 600 hastalık çalışma

Pages
143–150
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results alsodemonstrate that cytological materials are highly reliable for epidermalgrowth factor receptor mutation testing, and the probability of detectionof wild-type epidermal growth factor receptor is low in cases of thyroidtranscription factor-1 negativity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: This study aims to investigate the frequency, distribution,and morphological/immunohistochemical features of epidermal growthfactor receptor mutations and to examine the possible relationshipbetween the material type and technical success of mutation analysis inTurkish population with non-small cell lung cancer.Methods: Between September 2012 and December 2015, a total of499 consecutive, treatment-naïve patients (437 males, 163 females;mean age 61 years; range, 30 to 84 years) with primary or metastaticnon-small cell lung cancer who underwent epidermal growth factorreceptor mutation testing using Sanger sequencing method wereretrospectively analyzed.
📊
Key Findings & Data:The thyroidtranscription factor-1 and napsin A immunohistochemical stains wereperformed on tissue array blocks.Results: Seventy-five mutations were detected in 70 patients (14%).The success rate of testing and intact deoxyribonucleic acid fragmentlength were significantly higher in the cytological material, comparedto tissue specimens (p<0.001).
💡
Conclusion & Impact:These results alsodemonstrate that cytological materials are highly reliable for epidermalgrowth factor receptor mutation testing, and the probability of detectionof wild-type epidermal growth factor receptor is low in cases of thyroidtranscription factor-1 negativity.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: This study aims to investigate the frequency, distribution,and morphological/immunohistochemical features of epidermal growthfactor receptor mutations and to examine the possible relationshipbetween the material type and technical success of mutation analysis inTurkish population with non-small cell lung cancer.Methods: Between September 2012 and December 2015, a total of499 consecutive, treatment-naïve patients (437 males, 163 females;mean age 61 years; range, 30 to 84 years) with primary or metastaticnon-small cell lung cancer who underwent epidermal growth factorreceptor mutation testing using Sanger sequencing method wereretrospectively analyzed. Archival records and hematoxylin-eosine andimmunohistochemically stained sections were re-examined. The thyroidtranscription factor-1 and napsin A immunohistochemical stains wereperformed on tissue array blocks.Results: Seventy-five mutations were detected in 70 patients (14%).The success rate of testing and intact deoxyribonucleic acid fragmentlength were significantly higher in the cytological material, comparedto tissue specimens (p<0.001). The mutation rate in adenocarcinomaswas 33.9% for women and 9.4% for men. The most common mutationwas L746-E750del in exon 19 (29.3%), followed by the L858R mutationin exon 21 (28%). The mutation rate was the highest in micropapillary(40%) and lowest in solid (5.4%) adenocarcinomas. All epidermal growthfactor receptor mutations, except for one, were positive for the thyroidtranscription factor-1. The single nucleotide polymorphism Q787Q inexon 20 was observed in 79.6% of patients.Conclusion: The frequency and distribution of epidermal growthfactor receptor mutations in the Turkish patients with non-small celllung cancer are similar to the European populations. These results alsodemonstrate that cytological materials are highly reliable for epidermalgrowth factor receptor mutation testing, and the probability of detectionof wild-type epidermal growth factor receptor is low in cases of thyroidtranscription factor-1 negativity.

Özet

Amaç: Bu çalışmada küçük hücreli dışı akciğer kanserli Türk topolumunda epidermal büyüme faktör reseptör mutasyonlarının sıklığı, dağılımı ve morfolojik/immünhistokimyasal özellikleri araştırıldı ve materyal tipi ve mutasyon analizinin teknik başarısı arasındaki muhtemel ilişki incelendi. Çalışma planı: Eylül 2012 - Aralık 2015 tarihleri arasında Sanger sekanslama yöntemi ile epidermal büyüme faktör reseptör mutasyon testi yapılan, daha önce tedavi edilmemiş, primer veya metastatik küçük hücreli dışı akciğer kanserli toplam 499 ardışık hasta (437 erkek, 163 kadın; ort. yaş 61 yıl; dağılım, 30-84 yıl) retrospektif olarak incelendi. Arşiv kayıtları ve hematoksilen-eozin ve immünohistokimya boyalı kesitler yeniden değerlendirildi. Doku array bloklarında tiroid transkripsiyon faktör-1 ve napsin A immünohistokimyasal boyamaları yapıldı. Bulgular: Yetmiş hastada (%14) 75 mutasyon saptandı. Sitolojik materyallerde analizin başarı oranı ve intakt deoksiribonükleik asit parça uzunluğu, doku materyallerine kıyasla, anlamlı olarak daha yüksekti (p<0.001). Kadınlarda mutasyon oranı %33.9 ve erkeklerde %9.4 idi. En sık görülen mutasyon ekzon 19’da L746-E750del (%29.3) olup, bunu ekzon 21’de L858R (%28) mutasyonu izledi. Mutasyon oranı en yüksek mikropapillerde (%40) ve en düşük solid adenokarsinomalarda (%5.4) izlendi. Biri hariç, epidermal büyüme faktör reseptör mutasyonlarının tümünde tiroid transkripsiyon faktör-1 pozitifliği mevcut idi. Hastaların %79.6’sında ekzon 20’de tekli nükleotid polimorfizmi (Q787Q) izlendi. Sonuç: Küçük hücreli dışı akciğer kanserli Türk hastalarda epidermal büyüme faktör reseptör mutasyonlarının görülme sıklığı ve dağılımı Avrupa toplumları ile benzerdir. Ayrıca bu sonuçlar, epidermal büyüme faktör reseptör mutasyon analizi için sitolojik materyallerin son derece güvenilir olduğunu göstermekle birlikte, tiroid transkripsiyon faktör-1 negatif olgularda mutasyona rastlama ihtimali çok düşüktür.

🔖

Cite This Article

ÖZAKINCI, H., SAK, S. D., MUSAYEVA, M., BOYACIGİL, Ş., COŞKUN, Ö. (2022). Evaluation of epidermal growth factor receptor mutations and thyroid transcription factor-1 status in Turkish non-small cell lung carcinoma patients: A study of 600 cases from a single center. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 28 - Sayı: 1, 143–150. https://ajindex.com/articles/423667

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Lai Y, Zhang Z, Li J, Sun D, Zhou Y, Jiang T, et al. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. Int J Mol Sci 2013;14:24549-59
  2. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012;7:323-30
  3. Papadopoulou E, Tsoulos N, Tsirigoti A, Apessos A, Agiannitopoulos K, Metaxa-Mariatou V, et al. Determination of EGFR and KRAS mutational status in Greek non-smallcell lung cancer patients. Oncol Lett 2015;10:2176-84
  4. Ozluk Y, Firat P, Yegen G, Hocaoglu J, Tas S, Yilmazbayhan D. EGFR mutation testing using archivalstained smears in non-small cell lung carcinoma. Cytopathology 2017;28:35-45
  5. Skov BG, Høgdall E, Clementsen P, Krasnik M, Larsen KR, Sørensen JB, et al. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. APMIS 2015;123:108-15
  6. Chen Z, Liu X, Zhao J, Yang H, Teng X. Correlation of EGFR mutation and histological subtype according to the IASLC/ ATS/ERS classification of lung adenocarcinoma. Int J Clin Exp Pathol 2014;7:8039-45
  7. Ninomiya H, Hiramatsu M, Inamura K, Nomura K, Okui M, Miyoshi T, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009;63:235-40
  8. Szumera-Ciećkiewicz A, Olszewski WT, Tysarowski A, Kowalski DM, Głogowski M, Krzakowski M, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol 2013;6:2800-12
  9. Cetin Z, Ozbilim G, Erdogan A, Luleci G, Karauzum SB. Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. Med Oncol 2010;27:853-60
  10. Baykara O, Tansarikaya M, Demirkaya A, Kaynak K, Tanju S, Toker A, et al. Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients. Exp Ther Med 2013;5:495-8
  11. Akca H, Demiray A, Yaren A, Bir F, Koseler A, Iwakawa R, et al. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer